Galapagos Eyes Rare European Biotech Heavyweight Title, Launches $338m Offering
Galapagos is seeking $338m via a US public offering to fund Phase III studies for its lead drug filgotinib in various new immunology and inflammation indications. The biotech will also use the cash to prepare for its evolution into a commercial organization in the next few years, when it hopes to start promoting the drug in Europe for the treatment of rheumatoid arthritis. Ultimately it wants to be a major European biotech leader.
You may also be interested in...
Gilead has once more been mentioned as a prospective acquirer of Tesaro, but analysts at Datamonitor Healthcare's PharmaVitae believe that CAR-T and NASH are the areas where the company is more likely to seek buys that reduce its reliance on hepatitis C and HIV therapies.
If the JAK inhibitor codenamed TD-1473 proves effective in Crohn’s disease and ulcerative colitis, the clinical, regulatory and commercial know-how in IBD from partner Janssen could help Theravance pocket $1bn.
OncoMed lays off half its employees after a series of recent clinical setbacks. Meanwhile, six public companies raise $1.64bn in $100m-plus follow-on and debt offerings, SV Health Investors closed a $400m venture capital fund and eight therapeutics firms grabbed $247.5m in VC cash.